Newly developed nomenclature (Neuroscience-based Nomenclature)

Hiroyuki Uchida, Shigeto Yamawaki

Research output: Contribution to journalArticle

Abstract

The current nomenclature is based on clinical indications; for example, drugs used for mania and psychosis are classified as "mood stabilizers" and "antipsychotic drugs", respectively. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. In addition, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. To overcome these limitations of the current nomenclature, following an initiative of the European Congress of Neuropsychopharmacology (ECNP), a taskforce for psychotropic nomenclature was established with representatives from 5 international organizations, including the Asian College of Neuropsychopharmacology (AsCNP). The mission of this taskforce is to provide a pharmacologically-driven (rather than indication-based) nomenclature, which is now referred to as Neuroscience-based Nomenclature (NbN). The NbN project has just started. Since it always takes time to change the culture, we understand the transition will likely involve some expected and unexpected responses from the field. However, we believe that such responses and feedback will surely improve the quality of the NbN, which in turn will be beneficial for clinicians, researchers, and patients as well as their caregivers.

Original languageEnglish
Pages (from-to)69-71
Number of pages3
JournalNihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology
Volume36
Issue number3
Publication statusPublished - 2016 Jun 1

Fingerprint

Neurosciences
Terminology
Caregivers
Bipolar Disorder
Pharmaceutical Preparations
Psychotic Disorders
Antipsychotic Agents
Names
Research Personnel
Organizations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Newly developed nomenclature (Neuroscience-based Nomenclature). / Uchida, Hiroyuki; Yamawaki, Shigeto.

In: Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, Vol. 36, No. 3, 01.06.2016, p. 69-71.

Research output: Contribution to journalArticle

@article{c5835bd0fdae46caaf3059ab38950f93,
title = "Newly developed nomenclature (Neuroscience-based Nomenclature)",
abstract = "The current nomenclature is based on clinical indications; for example, drugs used for mania and psychosis are classified as {"}mood stabilizers{"} and {"}antipsychotic drugs{"}, respectively. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. In addition, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. To overcome these limitations of the current nomenclature, following an initiative of the European Congress of Neuropsychopharmacology (ECNP), a taskforce for psychotropic nomenclature was established with representatives from 5 international organizations, including the Asian College of Neuropsychopharmacology (AsCNP). The mission of this taskforce is to provide a pharmacologically-driven (rather than indication-based) nomenclature, which is now referred to as Neuroscience-based Nomenclature (NbN). The NbN project has just started. Since it always takes time to change the culture, we understand the transition will likely involve some expected and unexpected responses from the field. However, we believe that such responses and feedback will surely improve the quality of the NbN, which in turn will be beneficial for clinicians, researchers, and patients as well as their caregivers.",
author = "Hiroyuki Uchida and Shigeto Yamawaki",
year = "2016",
month = "6",
day = "1",
language = "English",
volume = "36",
pages = "69--71",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Newly developed nomenclature (Neuroscience-based Nomenclature)

AU - Uchida, Hiroyuki

AU - Yamawaki, Shigeto

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The current nomenclature is based on clinical indications; for example, drugs used for mania and psychosis are classified as "mood stabilizers" and "antipsychotic drugs", respectively. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. In addition, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. To overcome these limitations of the current nomenclature, following an initiative of the European Congress of Neuropsychopharmacology (ECNP), a taskforce for psychotropic nomenclature was established with representatives from 5 international organizations, including the Asian College of Neuropsychopharmacology (AsCNP). The mission of this taskforce is to provide a pharmacologically-driven (rather than indication-based) nomenclature, which is now referred to as Neuroscience-based Nomenclature (NbN). The NbN project has just started. Since it always takes time to change the culture, we understand the transition will likely involve some expected and unexpected responses from the field. However, we believe that such responses and feedback will surely improve the quality of the NbN, which in turn will be beneficial for clinicians, researchers, and patients as well as their caregivers.

AB - The current nomenclature is based on clinical indications; for example, drugs used for mania and psychosis are classified as "mood stabilizers" and "antipsychotic drugs", respectively. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. In addition, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. To overcome these limitations of the current nomenclature, following an initiative of the European Congress of Neuropsychopharmacology (ECNP), a taskforce for psychotropic nomenclature was established with representatives from 5 international organizations, including the Asian College of Neuropsychopharmacology (AsCNP). The mission of this taskforce is to provide a pharmacologically-driven (rather than indication-based) nomenclature, which is now referred to as Neuroscience-based Nomenclature (NbN). The NbN project has just started. Since it always takes time to change the culture, we understand the transition will likely involve some expected and unexpected responses from the field. However, we believe that such responses and feedback will surely improve the quality of the NbN, which in turn will be beneficial for clinicians, researchers, and patients as well as their caregivers.

UR - http://www.scopus.com/inward/record.url?scp=85004065397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004065397&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 69

EP - 71

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

IS - 3

ER -